Home » Stocks » EBS

Emergent BioSolutions, Inc. (EBS)

Stock Price: $82.80 USD 0.35 (0.42%)
Updated December 4, 3:11 PM EST - Market open

EBS Stock Price Chart

Key Info

Market Cap 4.39B
Revenue (ttm) 1.33B
Net Income (ttm) 166.60M
Shares Out 53.00M
EPS (ttm) 3.11
PE Ratio 26.60
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $82.80
Previous Close $82.45
Change ($) 0.35
Change (%) 0.42%
Day's Open 82.00
Day's Range 82.00 - 84.17
Day's Volume 235,474
52-Week Range 49.34 - 134.94

EBS Stock News

The Motley Fool - 1 week ago

Investors have been selling these stocks, but patient investors should take advantage of the opportunity.

Other stocks mentioned: CVS, FLGT
The Motley Fool - 1 week ago

Could these stocks be winners regardless of which coronavirus vaccine comes out on top?

Other stocks mentioned: COLD
Zacks Investment Research - 2 weeks ago

Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.

The Motley Fool - 3 weeks ago

While profitability came in above estimates, the company missed big on the top line.

Zacks Investment Research - 4 weeks ago

Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance.

Seeking Alpha - 4 weeks ago

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 weeks ago

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 1 month ago

On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.

Zacks Investment Research - 1 month ago

Emergent Biosolutions (EBS) closed the most recent trading day at $90.77, moving -0.55% from the previous trading session.

Seeking Alpha - 1 month ago

Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in th...

Zacks Investment Research - 1 month ago

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

Is (EBS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 month ago

In the latest trading session, Emergent Biosolutions (EBS) closed at $99.55, marking a +1.86% move from the previous day.

Zacks Investment Research - 1 month ago

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

GlobeNewsWire - 1 month ago

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the f...

The Motley Fool - 1 month ago

Blame it on Johnson & Johnson's pause of a late-stage study of its coronavirus vaccine candidate.

Zacks Investment Research - 1 month ago

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Other stocks mentioned: CLLS, TMO, VRTX
The Motley Fool - 1 month ago

Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.

Other stocks mentioned: DGX, REGN
GlobeNewsWire - 1 month ago

GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therap...

Zacks Investment Research - 1 month ago

Is (EBS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 2 months ago

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

Other stocks mentioned: BGNE, HZNP, RGEN
Zacks Investment Research - 2 months ago

Emergent BioSolutions has been struggling lately, but the selling pressure may be coming to an end soon.

Forbes - 2 months ago

Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105.

Zacks Investment Research - 3 months ago

Is (EBS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 3 months ago

In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.

Other stocks mentioned: AAWW, DQ, ETSY, STMP
Zacks Investment Research - 3 months ago

Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most

Other stocks mentioned: AZPN, DKS, DY, HOME
Zacks Investment Research - 3 months ago

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 3 months ago

As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Marvin L. White as a Class II direc...

The Motley Fool - 3 months ago

Convalescent plasma holds promise for treating COVID-19, but it's still unproven.

Other stocks mentioned: ADMA, KMDA
Zacks Investment Research - 3 months ago

Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research - 3 months ago

Here we discuss five biotech companies recording impressive growth so far in 2020.

Other stocks mentioned: ALRN, CLDX, HZNP, NVAX
The Motley Fool - 3 months ago

Either company could win the race to develop a COVID-19 vaccine, but one has an easier path to victory.

Other stocks mentioned: BNTX
Zacks Investment Research - 3 months ago

Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the fo...

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the...

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the...

CNBC Television - 3 months ago

Emergent BioSolutions CEO on Johnson & Johnson, AstraZeneca vaccine partnerships

Emergent BioSolutions CEO Bob Kramer joined Jim Cramer on "Mad Money" to discuss the biopharmaceutical company's role in the quest to bring a Covid-19 vaccine to market.

Other stocks mentioned: JNJ, AZN
Forbes - 3 months ago

Despite a stellar 2.6x rise since the March 23 lows of this year, at the current price of around $130 per share we believe Emergent Biosolutions, best known for its vaccines, antibody therapeu...

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 mil...

Zacks Investment Research - 3 months ago

Top Ranked Momentum Stocks to Buy for August 7th

Other stocks mentioned: BMCH, FND, SANM
Seeking Alpha - 3 months ago

Emergent BioSolutions: The Indirect COVID-19 Vaccine Play Looks Undervalued

Zacks Investment Research - 3 months ago

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research - 3 months ago

Investors who have the tendency to take a high level of risk can choose momentum stocks.

Other stocks mentioned: BCC, CCS, DECK
The Motley Fool - 3 months ago

These two stocks weathered the March crash without incident.

Other stocks mentioned: VRTX
GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal...

GlobeNewsWire - 4 months ago

GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount of...

Investors Business Daily - 4 months ago

The IBD SmartSelect Composite Rating for Emergent Biosolutions rose from 94 to 99 Monday. The post Composite Rating For Emergent Biosolutions Rises To 99 appeared first on Investor's Business...

Yahoo Finance - 4 months ago

Coronavirus vaccine: Emergent CEO discusses being ready to manufacture coronavirus vaccines

Emergent Biosolutions CEO Bob Kramer joins Yahoo Finance Akiko Fujita to discuss the company's earnings results and his outlook on developing a coronavirus vaccine.

The Motley Fool - 4 months ago

The expert in bioterrorism and emerging infectious diseases had a great second quarter, with more to come.

About EBS

Emergent BioSolutions, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a ty... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Nov 15, 2006
CEO
Robert Kramer
Employees
1,834
Stock Exchange
NYSE
Ticker Symbol
EBS
Full Company Profile

Financial Performance

In 2019, EBS's revenue was $1.11 billion, an increase of 41.36% compared to the previous year's $782.40 million. Earnings were $54.50 million, a decrease of -13.08%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for EBS is 111.29, which is an increase of 34.41% from the latest price.

Price Target
$111.29
(34.41% upside)